FDA has published notice of four emergency animal-drug authorizations for the prevention or treatment of New World screwworm infestations. The October 15 publication announces authorizations already issued on August 7, August 13, August 27 and September 3, 2026.
The notice describes different products, animals and permitted uses. It does not create one interchangeable treatment option for every animal.
Different animals and uses
FDA says the authorization requested by Elanco concerns an application on or around wounds to prevent infestations in specified livestock and captive or captured wildlife.
The authorization requested by Zoetis concerns treatment in dogs and puppies. Bimeda's authorization concerns prevention in cattle. The authorization requested by Sergeant's Pet Care Products concerns treatment and prevention in qualifying dogs, puppies, cats and kittens.
These are the notice's descriptions of scope. They are not dosing instructions, and the categories should not be combined into permission to use any of the products for any of the listed species.
Emergency permission has conditions
The notice says each authorization contains conditions governing emergency use. It explains the statutory framework FDA uses to permit emergency use of animal drugs.
FDA ties the authorizations to an August 18, 2025 determination and declaration by the Secretary of Health and Human Services concerning the potential emergency involving New World screwworm.
That earlier legal basis and today's publication are separate events. The notice should not be read as announcing a newly confirmed U.S. outbreak on October 15.
An emergency authorization is also distinct from unconditional approval for every use of a product.
Read the individual authorization
The Register text points readers to electronic access to the authorizations and FDA's veterinary information. Subsequent reissuances may appear on FDA's website.
The individual authorization letters appear as images omitted from the searchable text read for this report. Their complete restrictions, administration instructions and any withdrawal requirements were not reviewed. The announcement alone cannot support instructions for administering a product.